GlobeNewswire: CombiMatrix Corporation Contains the last 10 of 279 releaseshttp://www.globenewswire.com/External?Length=42024-03-19T08:20:19ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2017/11/10/1184789/0/en/CombiMatrix-Corporation-Stockholders-Approve-Merger-Agreement-With-Invitae-Corporation.html?f=22&fvtc=4&fvtv=6952CombiMatrix Corporation Stockholders Approve Merger Agreement With Invitae Corporation2017-11-10T21:15:49Z<![CDATA[IRVINE, Calif., Nov. 10, 2017 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (NASDAQ:CBMX) ("CombiMatrix" or the "Company"), a family health molecular diagnostics company specializing in DNA-based reproductive health and pediatric testing services, announced today that, based upon the final vote count for the Company’s Special Meeting of Stockholders held today, a majority of its stockholders voted to approve the previously announced merger agreement with Invitae Corporation (NYSE:NVTA) (“Invitae”), pursuant to which the Company would become a wholly owned subsidiary of Invitae upon closing of the proposed merger.]]>https://www.globenewswire.com/news-release/2017/11/06/1174865/0/en/CombiMatrix-Corporation-Reports-Third-Quarter-2017-Financial-and-Operating-Results.html?f=22&fvtc=4&fvtv=6952CombiMatrix Corporation Reports Third Quarter 2017 Financial and Operating Results2017-11-06T11:00:00Z<![CDATA[IRVINE, Calif., Nov. 06, 2017 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (NASDAQ:CBMX), a family health molecular diagnostics company specializing in DNA-based reproductive health and pediatric testing services, announces financial and operating results for the three and nine months ended September 30, 2017.]]>https://www.globenewswire.com/news-release/2017/11/02/1173901/0/en/CombiMatrix-Corporation-Reminds-Shareholders-to-Vote-FOR-the-Merger-With-Invitae-Corporation.html?f=22&fvtc=4&fvtv=6952CombiMatrix Corporation Reminds Shareholders to Vote "FOR" the Merger With Invitae Corporation2017-11-02T20:55:10Z<![CDATA[Although 96% of Votes Cast to Date Are in Favor of the Merger, a Majority of Shares Outstanding Must Vote “FOR” the Transaction Although 96% of Votes Cast to Date Are in Favor of the Merger, a Majority of Shares Outstanding Must Vote “FOR” the Transaction]]>https://www.globenewswire.com/news-release/2017/11/01/1172604/0/en/Leading-Independent-Proxy-Advisory-Firms-ISS-and-Glass-Lewis-Recommend-CombiMatrix-Corporation-Shareholders-Vote-FOR-the-Proposed-Merger-with-Invitae-Corporation.html?f=22&fvtc=4&fvtv=6952Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend CombiMatrix Corporation Shareholders Vote "FOR" the Proposed Merger with Invitae Corporation2017-11-01T20:05:00Z<![CDATA[IRVINE, Calif., Nov. 01, 2017 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (NASDAQ:CBMX) ("CombiMatrix" or the "Company"), a family health molecular diagnostics company specializing in DNA-based reproductive health and pediatric testing services, today announced that Institutional Shareholder Services Inc. (ISS) and Glass, Lewis & Co., LLC (Glass Lewis) have both recommended that CombiMatrix shareholders vote "FOR" the proposed merger with Invitae Corporation as described in the Company's proxy statement/prospectus for the special meeting of its shareholders to be held at 1:00 p.m., local time, on November 10, 2017.]]>https://www.globenewswire.com/news-release/2017/10/20/1150837/0/en/CombiMatrix-to-Present-New-Data-from-a-Large-Scale-Analysis-of-Genomic-Abnormalities-Impacting-Multiple-Stages-of-Human-Growth-and-Development-Starting-from-Conception-through-Chil.html?f=22&fvtc=4&fvtv=6952CombiMatrix to Present New Data from a Large-Scale Analysis of Genomic Abnormalities Impacting Multiple Stages of Human Growth and Development Starting from Conception through Childhood at the American Society of Human Genetics Annual Meeting2017-10-20T10:00:00Z<![CDATA[IRVINE, Calif., Oct. 20, 2017 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (NASDAQ:CBMX), a family health molecular diagnostics company specializing in DNA-based reproductive health and pediatric testing services, announces the presentation of new data from a large-scale, first-of-its kind study providing a comprehensive assessment of chromosomal imbalances and their adverse impact upon human growth and development from conception to childhood. Results from nearly 32,000 samples analyzed in this study indicate that genomic alterations decrease in frequency and severity from conception through development into childhood. Trilochan Sahoo, M.D., FACMG, CombiMatrix Vice President of Clinical Affairs and Director of Cytogenetics, will discuss these results today at the American Society of Human Genetics Annual Meeting (ASHG) in Orlando, Fla.]]>https://www.globenewswire.com/news-release/2017/09/25/1131983/0/en/CombiMatrix-Sets-Record-Date-and-Special-Stockholders-Meeting-Date-Regarding-Proposed-Merger-with-Invitae.html?f=22&fvtc=4&fvtv=6952CombiMatrix Sets Record Date and Special Stockholders Meeting Date Regarding Proposed Merger with Invitae2017-09-25T10:00:00Z<![CDATA[IRVINE, Calif., Sept. 25, 2017 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (NASDAQ:CBMX) (“CombiMatrix” or the “Company”), a family health molecular diagnostics company specializing in DNA-based reproductive health and pediatric testing services, announced today it has set important dates for a special meeting of its stockholders to vote on matters related to the proposed merger with Invitae Corporation (“Invitae”).]]>https://www.globenewswire.com/news-release/2017/08/03/1071895/0/en/CombiMatrix-Corporation-Reports-Second-Quarter-2017-Financial-and-Operating-Results.html?f=22&fvtc=4&fvtv=6952CombiMatrix Corporation Reports Second Quarter 2017 Financial and Operating Results2017-08-03T10:00:00Z<![CDATA[IRVINE, Calif., Aug. 03, 2017 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (NASDAQ:CBMX), a family health molecular diagnostics company specializing in DNA-based reproductive health and pediatric testing services, announces financial and operating results for the three and six months ended June 30, 2017.]]>https://www.globenewswire.com/news-release/2017/07/31/1065172/0/en/CombiMatrix-Enters-Into-Merger-Agreement-with-Invitae-Corporation-to-be-Acquired-for-33-Million-in-Invitae-Common-Stock.html?f=22&fvtc=4&fvtv=6952CombiMatrix Enters Into Merger Agreement with Invitae Corporation to be Acquired for $33 Million in Invitae Common Stock2017-07-31T20:58:31Z<![CDATA[$27 million offered to holders of CombiMatrix Common Stock (Nasdaq: CBMX) subject to certain adjustments]]>https://www.globenewswire.com/news-release/2017/05/22/994532/0/en/CombiMatrix-to-Present-at-Upcoming-Investor-Conferences.html?f=22&fvtc=4&fvtv=6952CombiMatrix to Present at Upcoming Investor Conferences2017-05-22T10:00:00Z<![CDATA[IRVINE, Calif., May 22, 2017 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (NASDAQ:CBMX), a family health molecular diagnostics company specializing in DNA-based reproductive health and pediatric testing services, announces that management will present at two upcoming investor conferences:]]>https://www.globenewswire.com/news-release/2017/05/04/979304/0/en/CombiMatrix-Corporation-Reports-First-Quarter-2017-Financial-and-Operating-Results.html?f=22&fvtc=4&fvtv=6952CombiMatrix Corporation Reports First Quarter 2017 Financial and Operating Results2017-05-04T20:05:00Z<![CDATA[Achieves record reproductive health revenues on higher test volumes and average revenue per test, expands gross margin, significantly narrows operating loss and reports record cash collections]]>